Revolution Medicines reports overall‑survival advantage of daraxonrasib across pancreatic cancer sub‑groups
+1 new source since this summary was written
Revolution Medicines presented late‑breaking subgroup results from its Phase 3 RASolute 302 trial at the ESMO Congress. The drug daraxonrasib (RASONQUE) extended median overall survival to 13.2 months versus 6.7 months with standard chemotherapy, with a hazard ratio of 0.40. Benefit was observed in all examined RAS genotype groups, including patients without a detectable tumor RAS mutation.
Why it matters
The company says the data support broader use of daraxonrasib in metastatic pancreatic cancer and should drive additional commercial uptake. The U.S. approval and a positive EU regulatory opinion position the product for near‑term revenue growth.
Key facts
- 1Median overall survival was 13.2 months with daraxonrasib and 6.7 months with chemotherapy, hazard ratio 0.40. stocktitan.net
- 2The trial enrolled 248 patients on daraxonrasib and 252 patients on investigator‑selected chemotherapy. stocktitan.net
- 3Analyses were based on data cut off on 10 February 2026, with a median follow‑up of 8.5 months. stocktitan.net
- 4Hazard ratios by RAS genotype were: G12D 0.49, G12V 0.32, G12R 0.61, Q61 0.37, and no identified mutation 0.43. investing.com
- 5Daraxonrasib received U.S. FDA approval in August 2026 for previously treated metastatic pancreatic adenocarcinoma. investing.com
- 6The European Medicines Agency’s Committee issued a positive opinion, with regulatory reviews ongoing elsewhere. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.